Cervical cancer recommendations lift ‘minor overhang’ on Hologic, says Leerink

After the U.S. Preventive Services Task Force released a draft recommendation statement on screening for cervical cancer, Leerink noted that the newly released draft USPSTF recommendations maintain co-testing as a Grade A recommended test, which the firm argues lifts a “minor overhang” on Hologic (HOLX) and the company’s “market-leading” AptimaHPV/ThinPrep cervical cancer screening test. Given co-testing maintained its USPSTF recommendation, the firm believes physicians will continue to utilize this procedure, so it sees today’s news as “an incremental positive” for Hologic, on which the firm has an Outperform rating.